• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine (CAS No. 807297-46-7): A Comprehensive Overview

N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine (CAS No. 807297-46-7) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmacology. This compound, also known by its systematic name N-Methyl-2-(1-methylpiperidin-3-yl)ethanamine, is a derivative of piperidine and exhibits a unique chemical structure that makes it a valuable candidate for various pharmaceutical applications.

The chemical structure of N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine consists of a piperidine ring with a methyl group at the 1-position and an ethylamine side chain attached to the 3-position. The presence of the N-methyl group on the ethylamine side chain further enhances its chemical stability and biological activity. This structure is crucial in determining the compound's pharmacological properties, including its interactions with specific receptors and enzymes.

Recent studies have highlighted the potential therapeutic applications of N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine. One of the most promising areas of research is its use as a neuroprotective agent. In vitro and in vivo experiments have shown that this compound can effectively protect neurons from oxidative stress and inflammation, which are key factors in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The mechanism of action involves the modulation of intracellular signaling pathways, including the activation of antioxidant enzymes and the inhibition of pro-inflammatory cytokines.

In addition to its neuroprotective properties, N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine has been investigated for its potential as an antidepressant. Preclinical studies have demonstrated that this compound can enhance serotonin and norepinephrine levels in the brain, which are neurotransmitters known to play a crucial role in mood regulation. These findings suggest that N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine could be a promising candidate for the development of new antidepressant medications with fewer side effects compared to existing drugs.

The pharmacokinetic properties of N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine have also been extensively studied. Research has shown that this compound has good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for oral administration. Additionally, it has been found to have low toxicity and minimal adverse effects, which are important considerations for drug development.

Clinical trials are currently underway to evaluate the safety and efficacy of N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine in human subjects. Early results from phase I trials have been promising, with no significant adverse events reported. These trials are expected to provide more detailed information on the compound's therapeutic potential and its suitability for further clinical development.

In conclusion, N-Methyl-2-(1-methyl-3-piperidinyl)-1-ethanamine (CAS No. 807297-46-7) is a promising compound with a wide range of potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the fields of neuroprotection and antidepressant therapy. As ongoing studies continue to uncover new insights into its mechanisms of action and clinical efficacy, this compound holds significant promise for improving patient outcomes in various neurological and psychiatric disorders.

• 7144-05-0(4-(Aminomethyl)piperidine)
• 7149-42-0((1-methylpiperidin-4-yl)methanamine)
• 25549-16-0(Triisoctylamine)
• 65017-57-4(4-(Aminomethyl)-1-(n-butyl)piperidine)
• 1193-12-0(3,3-Dimethylpiperidine)
• 14613-37-7((1-methyl-3-piperidyl)methanamine)
• 35794-11-7(3,5-Dimethylpiperidine)
• 100-76-5(Quinuclidine)
• 126579-26-8(methyl[(piperidin-4-yl)methyl]amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)